Hematology/Oncology Clinics of North America 2001-08-01

Biologic response modifiers in pediatric cancer.

L L Worth, S S Jeha, E S Kleinerman

Index: Hematol. Oncol. Clin. North Am. 15(4) , 723-40, ix, (2001)

Full Text: HTML

Abstract

Biologic response modifiers are becoming an important addition to surgery, chemotherapy, and radiotherapy in the management of cancer. As this field of research grows and expands, more biologic response modifiers will be incorporated into therapeutic regimens. By stimulating the immune system to eradicate minimal residual disease, these agents may improve the disease-free and long-term survival rates of patients with a variety of malignancies. The challenge is to incorporate biologic response modifiers into the treatment armamentarium in ways that will maximize their tumorigenicity.


Related Compounds

Related Articles:

Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma.

2009-08-01

[Expert Rev. Anticancer Ther. 9(8) , 1035-49, (2009)]

Imunomodulative effect of liposomized muramyltripeptide phosphatidylethanolamine (L-MTP-PE) on mice with alveolar echinococcosis and treated with albendazole.

2008-09-01

[Parasitol. Res. 103(4) , 919-29, (2008)]

In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells.

1999-04-01

[Cancer Biother. Radiopharm. 14(2) , 121-8, (1999)]

Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update.

1998-10-01

[Cancer Biother. Radiopharm. 13(5) , 363-8, (1998)]

Effect of MTP on TNF-alpha in perfused rat liver after bacteremia and ischemia/reperfusion.

1998-05-01

[J. Surg. Res. 76(2) , 179-84, (1998)]

More Articles...